Ventana Medical Systems

What Ventana Medical Systems does

Ventana Medical Systems, Inc. is a tissue-based diagnostic solutions company founded in 1985 and headquartered in Tucson, United States. The company operates as a wholly-owned subsidiary of F. Hoffmann-La Roche Ltd, functioning as the VENTANA brand under Roche Diagnostics, and employs between 1,001 and 5,000 people globally. Ventana is a category leader in anatomic pathology, providing next-generation pathology lab instruments, cytology and tissue-based assays, and software solutions to hospital and clinical pathology laboratories worldwide. Its core products include automated slide staining systems for IHC/ISH workflows, high medical value diagnostic assays, digital pathology tools enabling whole slide imaging and virtual microscopy, companion diagnostics that connect patients to targeted therapies, and workflow integration and tissue research products. The company's technology stack combines proprietary hardware instrumentation with reagent-based assays and a growing digital/software layer, including AI-assisted image analysis developed in collaboration with PathAI.

Ventana's business model is anchored in the sale of medical instrumentation and consumable tissue-based assays to healthcare institutions, supplemented by licensing and royalty arrangements tied to companion diagnostics that pair with targeted therapies. Products are marketed and distributed globally through Roche Diagnostics' enterprise field sales organization and digital channels, targeting anatomic pathology labs, clinicians, pathologists, and oncology/healthcare institutions. Pricing is not publicly disclosed and is structured around enterprise contracts with healthcare providers, consistent with a B2B diagnostics sales motion. Customer relationships are reinforced by an installed base of automated staining instruments, which creates ongoing reagent and assay pull-through.

The company's strategic positioning centers on personalized healthcare and precision oncology, using companion diagnostics to identify patients who may benefit from targeted therapies. Operating geographies are global, served through Roche Diagnostics' distribution and support infrastructure. Recent strategic activity includes the February 2024 Roche-PathAI partnership to develop AI-powered companion diagnostics under the VENTANA brand, signaling investment in AI-augmented digital pathology and biomarker-driven precision medicine. As a Roche subsidiary, Ventana benefits from the parent company's regulatory, distribution, and R&D scale but does not publish standalone financials.

Name

Ventana Medical Systems

Legal name

Ventana Medical Systems

Website

https://ventana.com

Company type

Private

Founded year

1985

Operating status

Acquired

Headcount range

1,001–5,000 employees

Short description

Ventana Medical Systems is a Roche Diagnostics subsidiary that develops and sells the VENTANA portfolio of anatomic pathology instruments, tissue-based assays, digital pathology software, and companion diagnostics for hospitals, clinical labs, and oncology institutions worldwide.

Ownership category

akta.pro rank

Product category

Anatomic Pathology Diagnostics

NAICS

In-Vitro Diagnostic Substance Manufacturing (325413), Analytical Laboratory Instrument Manufacturing (334516)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Imaging Informatics & Workflow (PACS/RIS/VNA) (HLAHABAI)

akta.pro secondary industries

Universal Viewers & Enterprise Imaging Access (Zero-footprint/Diagnostic) (HLACALAD), Imaging Interoperability & Standards Enablement (DICOM/HL7/FHIR/IHE) (HLACALAJ)

Keywords

• Tissue diagnostics
• Anatomic pathology
• Companion diagnostics
• Digital pathology
• Slide staining systems

Headquarters

HQ city

Tucson

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Supply Chain, Operations, Personnel, Marketing or Sales, Infrastructure

Revenue model

1. Medical Instrumentation and Assays: VENTANA generates revenue through the sale of pathology lab instruments, automated staining systems, and tissue-based diagnostic assays to healthcare institutions and laboratories.
2. Companion Diagnostics: Companion diagnostic products that connect patients to targeted therapies, providing diagnostic solutions for precision oncology and personalized healthcare.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Ventana Medical Systems (VENTANA® brand, a Roche Diagnostics company) manufactures and sells next-generation pathology lab instruments, cytology and tissue-based diagnostic assays, and digital pathology software for anatomic pathology laboratories. The product portfolio spans automated slide staining systems (IHC/ISH), companion diagnostics that match patients to targeted therapies, digital pathology tools, workflow integration solutions, and tissue research products used by hospitals and clinical laboratories.

Product overview

VENTANA® is a comprehensive brand portfolio of anatomic pathology products under Roche Diagnostics, comprising next-generation automated slide staining systems (including IHC-ISH instruments), cytology and tissue-based assays, digital pathology tools (whole slide imaging and virtual microscopy software), companion diagnostics for targeted therapy selection, workflow integration solutions, and tissue research products. These products work together to enable anatomic pathology labs to deliver prompt and precise diagnostic results, with companion diagnostics connecting patients to appropriate targeted therapies and digital tools enabling diagnostic certainty through AI-assisted analysis.

Differentiator

Problem solved

Functional benefit

Products and services

• VENTANA® Automated Slide Staining Systems Next-generation pathology lab instruments that automate slide staining for immunohistochemistry (IHC) and in situ hybridization (ISH) testing, sold to anatomic pathology labs, hospitals, and clinical laboratories.
• VENTANA® Cytology and Tissue-Based Assays High medical value diagnostic assays for cytology and tissue-based testing, enabling diagnostic certainty and supporting targeted personalized therapies for anatomic pathology labs.
• VENTANA® Companion Diagnostics Companion diagnostic tests that identify biomarkers in patient tissue samples and match patients to the most targeted and appropriate therapies, supporting personalized healthcare and precision oncology.
• VENTANA® Digital Pathology Tools Software solutions for digital pathology including whole slide imaging, virtual microscopy, and telepathology capabilities that enable diagnostic certainty and enhanced clinical decision making for anatomic pathology labs.
• VENTANA® Workflow, Integration and Connectivity Solutions Solutions for integrating pathology lab workflows, enabling connectivity between instruments and systems to streamline operations in anatomic pathology labs.
• VENTANA® Tissue Research Products Discovery and tissue research products used by pharmaceutical and healthcare research applications for tissue-based investigations.

Quantifiable outcome

• VENTANA products enable anatomic pathology labs to deliver prompt and precise results, empowering clinicians to make timely and confident treatment decisions

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature5 records

Partnerships

One partnership is on record.

• PathAIcoreStrategic or Co-development Partner · 1 February 2024Roche and PathAI formed a partnership in February 2024 to develop AI-powered companion diagnostics. This collaboration focuses on creating advanced AI-driven diagnostic tools for precision medicine applications, combining PathAI's artificial intelligence capabilities with Roche's companion diagnostics expertise through the VENTANA brand.

Scale indicators4 records

Recent moves1 record

Expansion highlights5 records

Others

• Foundation Medicine: A Roche subsidiary and sibling entity to Ventana, providing tissue- and blood-based comprehensive genomic profiling CDx; competes with VENTANA CDx in oncology while sharing Roche pharma alignment and ecosystem.

Direct peers

• Leica Biosystems: A Danaher-owned anatomic pathology company offering automated staining systems, IHC/ISH reagents, and digital pathology solutions; directly competes with VENTANA across the histology lab workflow and is the closest comparable in instruments and consumables.
• Agilent (Dako pathology business): Through its Dako pathology franchise, Agilent provides IHC/ISH antibodies, staining instruments, and companion diagnostics — overlapping directly with VENTANA's assays, staining systems, and CDx business.
• Bio-Rad Laboratories: Operates a clinical diagnostics segment with histology, IHC reagents, and quality-control products for pathology labs; competes with VENTANA in IHC reagents and lab QC consumables.
• Philips (Digital Pathology): Offers whole-slide imaging scanners and digital pathology workflow software for anatomic pathology; directly competes with VENTANA's digital pathology tools and viewer integrations.
• Hamamatsu Photonics: A leading provider of whole-slide imaging scanners (NanoZoomer) used in digital pathology workflows; competes with VENTANA in the image acquisition layer of the digital pathology stack.

Broad incumbents

• Hologic: A diversified diagnostics and medical device company with adjacent molecular and tissue-based testing capabilities; broader portfolio but overlaps with VENTANA in anatomic pathology and women's health oncology diagnostics.
• Qiagen: Provides sample-prep technologies and companion diagnostic assays used alongside targeted therapies; overlaps with VENTANA in CDx development though more focused on molecular rather than tissue-based workflows.
• Guardant Health: Liquid biopsy leader with companion diagnostic tests for targeted oncology therapies; competes indirectly with VENTANA by offering an alternative CDx modality that could displace some tissue-based CDx demand.

Emerging players

• Bio-Techne: Supplies reagents, antibodies, and tissue-based research tools increasingly used in pathology and spatial biology workflows; an emerging competitor in specialty IHC and tissue assay reagents versus VENTANA.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/ventana

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ventana Medical Systems